Medidata initiated with a Buy at Guggenheim. Guggenheim analyst Glen Santangelo started Medidata Solutions with a Buy rating and $92 price target. The company has a strong competitive position and stands to benefit from increased cross-selling and industry trial activity, Santangelo tells investors in a research note. Further, he believes the stock at current levels offers a “compelling” entry point.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.